Zacks Research Issues Positive Forecast for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Equities researchers at Zacks Research lifted their Q2 2025 earnings estimates for Bausch Health Companies in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.05 per share for the quarter, up from their prior estimate of $1.04. The consensus estimate for Bausch Health Companies' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2026 earnings at $1.24 EPS, FY2026 earnings at $4.72 EPS and FY2027 earnings at $5.67 EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion.

Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada dropped their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.42.

Remove Ads

Bausch Health Companies Trading Down 1.3 %

BHC traded down $0.10 on Thursday, reaching $7.06. The stock had a trading volume of 1,088,804 shares, compared to its average volume of 2,701,436. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The business's 50-day moving average price is $7.21 and its two-hundred day moving average price is $7.67. The company has a market cap of $2.60 billion, a P/E ratio of -58.79, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59.

Hedge Funds Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently bought and sold shares of BHC. Mountain Hill Investment Partners Corp. acquired a new position in Bausch Health Companies during the fourth quarter worth about $56,000. Bank of Nova Scotia acquired a new position in Bausch Health Companies in the 4th quarter valued at about $83,000. One68 Global Capital LLC acquired a new position in Bausch Health Companies in the 4th quarter valued at about $90,000. Balyasny Asset Management L.P. acquired a new position in Bausch Health Companies in the 4th quarter valued at about $97,000. Finally, Alpine Global Management LLC acquired a new position in Bausch Health Companies in the 4th quarter valued at about $114,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.